Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Major Shareholder Sells 174,645 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par sold 174,645 shares of the business’s stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75. Following the sale, the insider directly owned 5,129,340 shares of the company’s stock, valued at approximately $86,942,313. The trade was a 3.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, March 26th, Venrock Healthcare Capital Par sold 39,986 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $18.28, for a total transaction of $730,944.08.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $19.33 on Friday. The stock has a market cap of $990.08 million, a price-to-earnings ratio of -4.89 and a beta of -0.35. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $9.23 and a fifty-two week high of $19.95. The firm’s 50-day simple moving average is $16.04 and its 200 day simple moving average is $14.46.

More KalVista Pharmaceuticals News

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a “buy” rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a “buy” rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a “market outperform”), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

Analysts Set New Price Targets

Several brokerages recently issued reports on KALV. Citizens Jmp cut their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Stifel Nicolaus lifted their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Needham & Company LLC lifted their price objective on shares of KalVista Pharmaceuticals from $35.00 to $36.00 and gave the stock a “buy” rating in a report on Wednesday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, KalVista Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds have recently bought and sold shares of KALV. BNP Paribas Financial Markets grew its stake in KalVista Pharmaceuticals by 47.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $55,000. Wolverine Asset Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth $57,000. KLP Kapitalforvaltning AS bought a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth $63,000. Finally, Truvestments Capital LLC boosted its holdings in shares of KalVista Pharmaceuticals by 253.8% in the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.